2025 Will Be A Major Year For ProKidney's Rilparencel In CKD Treatment

Group 1 - ProKidney (NASDAQ: PROK) is a biotech company focused on autologous cellular therapy for organ preservation, with its leading candidate being Rilparencel (React) for chronic kidney disease (CKD) [1] - Rilparencel utilizes patients' kidney cells to stabilize or slow down the progression of CKD [1]